Figure 1From: Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cellsJZL184 treatment reduced the level of microgliosis and total Aβ in the AD mouse model. One month daily treatment with JZL184 (40 mg/kg, i.p.) reduced the immunoreactivity of (A) Iba1 in temporal (TC) (P < 0.05) and parietal (PC) (P < 0.05) cortices and hippocampus (HC) (P < 0.01) in 5-month-old tg APdE9 mice when compared to vehicle-treated mice. Also, (B) TSPO targeting radioligand [18 F]GE-180 decreased slightly but statistically non-significantly in multiple brain areas, for example, in the hippocampi. The level of (C) GFAP did not decrease significantly. The level of (D) 6E10 was reduced in TC (P < 0.001) and PC (P < 0.01) and slightly in HC.Back to article page